Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody

Abstract

Purpose: Erlotinib is a novel therapeutic agent for cancer treatment. This study was performed to investigate therole of c-MET-PI3K-AKT pathway in the regulation of erlotinib-induced radiosensitization.Methods: A973 lung adenocarcinoma cells treated with 6 Gy of radiation were incubated in the presence oferlotinib. The apoptotic rate after 24 hours, the colony-formating rate after 14 days, and changes in the c-METexpression levels after 14 days of irradiation were examined. Surviving fractions in different treatment groups (blankcontrol, radiation alone, erlotinib alone, anti-c-MET monoclonal antibody alone, combined erlotinib and radiation,and combined erlotinib and radiation with anti-c-MET monoclonal antibody groups) were determined, the survivalcurves were plotted, and the sensitizer enhancement ratio was calculated using colony formation assays. Expressions ofc-MET, p-c-MET, PI3K, AKT, and p-AKT in cells in different treatment groups were examined by Western blot analysis. Results: The apoptotic rate in the combined erlotinib and radiation group was higher than those in single treatment groups; however, the colony-forming rate remained approximately 2.04 ± 1.02%. The expression of c-MET in colony-forming cells in the combined group significantly increased, and the blockade of c-MET activity significantly enhanced the radiosensitizing effect of erlotinib. The expression of c-Met, p-c-MET, PI3K, AKT, and p-AKT among colony-forming cells significantly decreased upon the inhibition of c-MET.Conclusions: Upregulated activity of the c-MET-PI3K-AKT pathway was found to be important for cell survival under combined the treatment with erlotinib and radiation. The blockade of the c-MET-PI3K-AKT signaling pathway enhanced the radiosensitizing effect of erlotinib.